Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

NCT03758287 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: CT053PTSA
DRUG: Gefitinib

Sponsor

Sunshine Lake Pharma Co., Ltd.